{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:52:46Z","timestamp":1725277966240},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,5,19]],"date-time":"2004-05-19T00:00:00Z","timestamp":1084924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Desmopressin [1\u2010deamino\u20108\u2010<jats:sc>d<\/jats:sc>\u2010arginine vasopressin (DDAVP)] has been successfully used in the treatment of type 1 von Willebrand disease (VWD) and mild haemophilia A (MHA). Data suggest that DDAVP can increase factor XI (FXI) plasma levels and may represent an effective treatment for mild FXI deficiency. We assessed the DDAVP response of FXI coagulant activity (FXI:C), FXI antigen (FXI:Ag), factor V coagulant activity (FV:C), and factor X coagulant activity (FX:C) in 33 individuals with VWD or MHA. DDAVP did not produce a clinically significant increase in FXI:C, FXI:Ag, FX:C or FV:C in any patient. The mean\u2003\u00b1\u2003SD FXI:C pre\u2010DDAVP (time 0) and at 1\u2003h post\u2010DDAVP was 90\u00b77 (\u00b122\u00b79)\u2003U\/dl and 92\u00b71 (\u00b120\u00b79)\u2003U\/dl, respectively. The mean (\u00b1SD) FXI:Ag at time 0 and 1\u2003h was 92\u00b72 (\u00b120\u00b71)\u2003U\/dl and 89\u00b79 (\u00b121\u00b73)\u2003U\/dl, respectively. There was a small reduction at 1\u2003h post\u2010DDAVP in both FV:C, from 101\u00b78 (\u00b120\u00b79)\u2003U\/dl to 97\u00b72 (\u00b121\u00b74)\u2003U\/dl (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001), and FX:C from 103 (\u00b119\u00b75)\u2003U\/dl to 98\u00b78 (\u00b118\u00b77)\u2003U\/dl (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b7001). No significant increase in FXI:C, FXI:Ag, FV:C or FX:C levels was seen at 4\u2003h post\u2010DDAVP. This study failed to demonstrate a clinically significant increase in the levels of FXI, FX or FV following administration of DDAVP.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2004.04988.x","type":"journal-article","created":{"date-parts":[[2004,6,14]],"date-time":"2004-06-14T08:25:57Z","timestamp":1087201557000},"page":"100-104","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease"],"prefix":"10.1111","volume":"126","author":[{"given":"B.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Riddell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. C.","family":"Nitu\u2010Whalley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,5,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440683.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0038-1648439","article-title":"Production and therapeutic use of a factor XI concentrate from plasma","volume":"67","author":"Bolton\u2010Maggs P.H.","year":"1992","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92237-3"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1758.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830330108"},{"key":"e_1_2_8_7_1","first-page":"221","article-title":"Response to desmopressin in patients with clinically severe type 1 and 2 von Willebrand disease: results of a multicentre European Study","volume":"6","author":"Federici A.","year":"2000","journal-title":"Haemophilia"},{"key":"e_1_2_8_8_1","first-page":"106","article-title":"Prophylactic use of desmopressin in surgery of six patients with symptomatic heterozygous factor XI deficiency [In Process Citation]","volume":"85","author":"Franchini M.","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000132844"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00190.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1975.tb00521.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1055\/s-0038-1649884","article-title":"Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double\u2010blind placebo\u2010controlled trial","volume":"74","author":"Rao A.K.","year":"1995","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1642471","article-title":"A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"71","author":"Sadler J.E.","year":"1994","journal-title":"Thrombosis and Haemostasis"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2004.04988.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2004.04988.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2004.04988.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:29:52Z","timestamp":1697380192000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2004.04988.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,19]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1111\/j.1365-2141.2004.04988.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2004.04988.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,19]]},"assertion":[{"value":"2004-05-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}